Savara Inc (SVRA) stock
SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.48+0.02 (+0.34%)
Close on Nov 17, 2026Market cap $920.46MP/E –Yield –
Savara r&d expenses
Research and development expenses are spending on new products and technology.
Savara's R&D Expenses for the twelve months ending Jun 30, 2026 was $86.84M, up 4.0% year over year. For fiscal 2025 it was $81.40M, up 4.3% from the year before. Over ten years it grew 34.1% a year on average. The highest annual figure on record is $81.40M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.40M | +4.3% |
| FY2024 | Dec 31, 2024 | $78.03M | +76.3% |
| FY2023 | Dec 31, 2023 | $44.26M | +58.8% |
| FY2022 | Dec 31, 2022 | $27.88M | -3.8% |
| FY2021 | Dec 31, 2021 | $28.99M | -17.3% |
| FY2020 | Dec 31, 2020 | $35.04M | -9.7% |
| FY2019 | Dec 31, 2019 | $38.78M | +4.3% |
| FY2018 | Dec 31, 2018 | $37.17M | +100.8% |
| FY2017 | Dec 31, 2017 | $18.51M | +126.3% |
| FY2016 | Dec 31, 2016 | $8.18M | +89.4% |
| FY2015 | Dec 31, 2015 | $4.32M | -77.8% |
| FY2014 | Dec 31, 2014 | $19.44M | +50.6% |
| FY2013 | Dec 31, 2013 | $12.90M | +59.5% |
| FY2012 | Dec 31, 2012 | $8.09M | +40.5% |
| FY2011 | Dec 31, 2011 | $5.76M | +56.1% |
| FY2010 | Dec 31, 2010 | $3.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.95M | +5.8% |
| Q1 FY2026 | Mar 31, 2026 | $23.40M | +22.1% |
| Q4 FY2025 | Dec 31, 2025 | $20.90M | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $20.59M | +1.4% |
| Q2 FY2025 | Jun 30, 2025 | $20.75M | +17.8% |
| Q1 FY2025 | Mar 31, 2025 | $19.16M | +14.0% |
| Q4 FY2024 | Dec 31, 2024 | $23.29M | +82.8% |
| Q3 FY2024 | Sep 30, 2024 | $20.31M | +46.5% |
| Q2 FY2024 | Jun 30, 2024 | $17.62M | +97.7% |
| Q1 FY2024 | Mar 31, 2024 | $16.81M | +92.3% |
| Q4 FY2023 | Dec 31, 2023 | $12.75M | +67.1% |
| Q3 FY2023 | Sep 30, 2023 | $13.87M | +70.1% |
| Q2 FY2023 | Jun 30, 2023 | $8.91M | +38.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.74M | +53.7% |
| Q4 FY2022 | Dec 31, 2022 | $7.63M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | $8.15M | +24.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.42M | -11.5% |
| Q1 FY2022 | Mar 31, 2022 | $5.68M | -25.1% |
| Q4 FY2021 | Dec 31, 2021 | $7.62M | -25.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.53M | +16.6% |
| Q2 FY2021 | Jun 30, 2021 | $7.25M | +19.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.59M | -42.5% |
| Q4 FY2020 | Dec 31, 2020 | $10.16M | +16.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.60M | -41.5% |
| Q2 FY2020 | Jun 30, 2020 | $6.08M | -41.9% |
| Q1 FY2020 | Mar 31, 2020 | $13.20M | +31.7% |
| Q4 FY2019 | Dec 31, 2019 | $8.72M | -11.5% |
| Q3 FY2019 | Sep 30, 2019 | $9.58M | +0.7% |
| Q2 FY2019 | Jun 30, 2019 | $10.46M | +12.9% |
| Q1 FY2019 | Mar 31, 2019 | $10.02M | +17.3% |
| Q4 FY2018 | Dec 31, 2018 | $9.86M | +53.2% |
| Q3 FY2018 | Sep 30, 2018 | $9.51M | +91.5% |
| Q2 FY2018 | Jun 30, 2018 | $9.27M | +122.6% |
| Q1 FY2018 | Mar 31, 2018 | $8.54M | +189.7% |
| Q4 FY2017 | Dec 31, 2017 | $6.44M | +84.5% |
| Q3 FY2017 | Sep 30, 2017 | $4.97M | +131.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.95M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.49M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.14M | – |
See a number that looks wrong?